Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
Raches Ella, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya D. Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Suresh Bhate, Sanjay Rai, Samiran Panda, Priya Abraham, Nivedita Gupta, Krishna M. Ella, Balram Bhargava, Krishna Mohan Vadrevu
Topics & Concepts
ImmunogenicityMedicineInterimDouble blindInterim analysisRandomized controlled trialInternal medicineAntibodyImmunologyAlternative medicinePlaceboPathologyHistoryArchaeologySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesSARS-CoV-2 detection and testing